A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
NO SOLID PHASE 3 TRIALS.
HAVE MANY FAILURES IN THE PIPELINE; ALOT OF COMPETETION FOR HEP C, INCLUDING INGENIX AND SCHERING WITH PROTEASE INHIBITORS COMING OUT. NEED NEW BLOOD COARSING THROUGH ITS VEINS OR COULD SETTLE IN AT 11-13.
another perfectly good review ruined because of all caps,,,reminds me of an old teletype with only one type face....
http://www.youtube.com/watch?v=eyCEexG9xjw